Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Metoprolol Succinate, TOPROL-XL®
Metoprolol · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Metoprolol Succinate ER Tablets, 50 mg | EXPERIMENTAL | Metoprolol Succinate ER Tablets, 50 mg of Dr.Reddy's Laboratories Ltd |
| TOPROL-XL ER Tablets 50 mg | ACTIVE_COMPARATOR | TOPROL-XL ER Tablets 50 mg of AstraZeneca |
| Metoprolol Succinate ER Tablets, 200 mg | EXPERIMENTAL | Metoprolol Succinate ER Tablets, 200 mg of Dr.Reddy's Laboratories Ltd |
| TOPROL-XL ER Tablets 200 mg | ACTIVE_COMPARATOR | TOPROL-XL ER Tablets 200 mg of AstraZeneca |
| Name | Type | Description |
|---|---|---|
| Metoprolol Succinate | DRUG | - |
Inclusion Criteria: Subjects were selected based on the following inclusion criteria: * Provide written informed consent. * Must be healthy, adult, human beings between 18 and 45 years of age(both inclusive) weighing at least 50 kg. * Having a body mass index between 18.5 and 24.9 (both inclusive)...
Metoprolol is a small molecule drug developed by Dr. Reddy's Laboratories Ltd, which trades under the ticker RDY. It is also known as metoprolol succinate. The drug is in Phase 1 clinical development, and its specific indications are undisclosed. Metoprolol is classified in the therapeutic area of Other.
Metoprolol targets ADRB1, also known as the beta-1 adrenergic receptor. It acts as an antagonist at this receptor. By blocking ADRB1, metoprolol interferes with the binding of endogenous catecholamines such as epinephrine and norepinephrine, thereby reducing their effects on target tissues.
Metoprolol is developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company that trades under the ticker symbol RDY. The company is responsible for the clinical development of metoprolol succinate, including the bioequivalence studies conducted to date.
Metoprolol is in Phase 1 clinical development. It has not been approved by the FDA for any indication based on the available information. The drug has completed two Phase 1 trials, and there are currently no active trials. It remains an investigational product.
Metoprolol has been studied in two completed Phase 1 clinical trials. NCT01694797 was a bioequivalence study of metoprolol succinate ER tablets 50 mg under fasting conditions, enrolling 48 healthy volunteers in India. NCT01673997 was a bioequivalence study of metoprolol succinate ER tablets 200 mg under fasting conditions, also enrolling 48 healthy volunteers in India.
Yes, Metoprolol is also known as metoprolol succinate. Metoprolol succinate is the extended-release salt form of metoprolol. Both names refer to the same active pharmaceutical ingredient developed by Dr. Reddy's Laboratories Ltd.